Lojuxta:Clinical Evaluation results27 Apr 2017 09:55
The study results have been presented in a paper entitled, "Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy", and published by Advances in Therapy, an international, peer-reviewed journal.
The following Professional endorsements in respect of of the data captured and emanating from evaluation of the use of Lojuxta in patients over a significant time-frame are, both extremely illuminating and encouraging:
Prof. Marcello Arca, Sapienza' University of Rome, commented:
"This real-world experience, has shown Lojuxta to be a very powerful and well tolerated cholesterol-lowering agent in patients with HoFH. The reduction in LDL-C that we observed is far higher than seen in clinical trials and higher than we can achieve with any other therapeutic option we have for patients with this difficult to treat and devastating disease. The ability to stop apheresis and still achieve LDL-C target levels in patients who had LDL-C levels up to 8 times the recommended level is remarkable".
Dr Helen Phillips, Head of Medical Affairs at Amryt, commented:
"We are delighted that these data have been published. Physicians used to believe that the LDL-C targets recommended by the European Atherosclerosis Society were impossible to achieve in HoFH but this is no-longer the case.
"These data are not unique to Italy - we have seen similar results in patients treated in Spain, Sweden and Netherlands. Unlike statins, ezetimibe and PCSK-9 inhibitors, Lojuxta works independently of LDL receptors which have little to no functionality in HoFH. Through this different mechanism of action, Lojuxta offers patients with HoFH an ability to reach the LDL-C levels of normal individuals and stop the incredibly burdensome and invasive procedure of apheresis. It offers the potential to transform the lives of patients with HoFH, with the addition of a capsule a day".
Sign In
Follow the stocks
